Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Kendall Lee Stevinson"'
Autor:
Kendall Lee Stevinson, C. Lance Cowey, Jenny Black-Shinn, Jennifer Frytak, Scot Ebbinghaus, Frank Xiaoqing Liu, Marley Boyd
Publikováno v:
Journal of Immunotherapy (Hagerstown, Md. : 1997)
The programmed death-1 inhibitor pembrolizumab has demonstrated efficacy and safety in clinical trials for treating advanced (unresectable/metastatic) melanoma. We investigated the real-world utilization of pembrolizumab and associated patient outcom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26929b8d903ce4233236703c8de60315
http://europepmc.org/articles/PMC5811239
http://europepmc.org/articles/PMC5811239
Autor:
Grant A. McArthur, Peter Mohr, Kendall Lee Stevinson, Reshma Shinde, Michael Weichenthal, Ana Banos Hernaez, Peter Kaskel, Paolo A. Ascierto, Ana Arance
Publikováno v:
The Oncologist
The objective of this study was to describe health care resource utilization and health care costs associated with the management of advanced melanoma patients receiving ipilimumab.
Background. There are limited real‐world data on health care
Background. There are limited real‐world data on health care
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9974987ef2f17c767991d5574958ec6b
http://europepmc.org/articles/PMC5553953
http://europepmc.org/articles/PMC5553953
Autor:
Kendall Lee Stevinson, Ruifeng Xu, Bartosz Chmielowski, J Wang, Frank Xiaoqing Liu, James M. Pellissier
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 23:184-194
Recent clinical trials have shown that pembrolizumab significantly prolonged progression-free survival and overall survival compared with ipilimumab in ipilimumab-naïve patients with unresectable or metastatic melanoma. However, there has been no pu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6796114a90e6f22d1ebaf68e50dcb2d7
https://doi.org/10.18553/jmcp.2017.23.2.184
https://doi.org/10.18553/jmcp.2017.23.2.184
Autor:
Kendall Lee Stevinson, Taito Esaki, Tara Matsuda, Frederick H. Wilson, Jhanelle E. Gray, Geoffrey I. Shapiro, Kim Cocks, Fabrice Barlesi, Alexander I. Spira, Qui Tran, Christophe Dooms, Andrew Trigg, Alessandra Curioni-Fontecedro
Publikováno v:
Journal of Clinical Oncology. 39:9057-9057
9057 Background: In the registrational phase 2 CodeBreaK 100 trial, sotorasib demonstrated a response rate of 37.1% with median duration of 10.0 months, a median progression-free survival of 6.8 months, and a tolerable safety profile in patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dcb7d90cc60f1ff7e12b01b65b06b9b6
https://doi.org/10.1200/jco.2021.39.15_suppl.9057
https://doi.org/10.1200/jco.2021.39.15_suppl.9057
Autor:
Aurelien Jamotte, Ann Xi, Partha Manas Das, Allison Petrilla, Nathan Markward, Kendall Lee Stevinson, Ehab Elkhouly, Barton Jones, Anne Murunga, Tara Matsuda, Anik R Patel
Publikováno v:
Journal of Clinical Oncology. 38:278-278
278 Background: The number of targeted therapies approved for treatment of mNSCLC has increased over the past 5 years. Strategies to identify eligible patients with actionable mutations for targeted therapy include simultaneous testing of ≥ 2 genes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::87e7d2f229284b3dbab0fa0cac8f84ec
https://doi.org/10.1200/jco.2020.38.29_suppl.278
https://doi.org/10.1200/jco.2020.38.29_suppl.278
Autor:
Kendall Lee Stevinson, Evelina Zimovetz, Bartosz Chmielowski, Josephine Mauskopf, J Wang, Frank Xiaoqing Liu, Catherine Copley-Merriman
Publikováno v:
Medicine
Supplemental Digital Content is available in the text
Background: Treatments for advanced melanoma are associated with different adverse events (AEs), which may be costly to manage. This study aimed to evaluate direct costs associated with manag
Background: Treatments for advanced melanoma are associated with different adverse events (AEs), which may be costly to manage. This study aimed to evaluate direct costs associated with manag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::674e663432b92fb6d8de65c00bdc05d3
https://doi.org/10.1097/md.0000000000011736
https://doi.org/10.1097/md.0000000000011736
Publikováno v:
Value in Health. 19:A157-A158
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d80badc77f82eda425ad922e92ac73f7
https://doi.org/10.1016/j.jval.2016.03.1467
https://doi.org/10.1016/j.jval.2016.03.1467
Autor:
Debra A. Patt, Marley Boyd, Jenny Black-Shinn, Kendall Lee Stevinson, Charles Lance Cowey, Frank Xiaoqing Liu, Scot Ebbinghaus
Publikováno v:
Journal of Clinical Oncology. 35:e21015-e21015
e21015 Background: PD-1 monoclonal antibodies are promising immunotherapies approved for treatment of patients (pts) with advanced melanoma. As the first US FDA approved PD-1 antibody, pembrolizumab (pembro) has demonstrated efficacy and safety in cl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3d26a04accdeb8a945fed9f9da0de577
https://doi.org/10.1200/jco.2017.35.15_suppl.e21015
https://doi.org/10.1200/jco.2017.35.15_suppl.e21015
Publikováno v:
Value in Health. 19:A138
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5c130595f8ff0635d02b1ed4def63760
https://doi.org/10.1016/j.jval.2016.03.1650
https://doi.org/10.1016/j.jval.2016.03.1650
Autor:
Kendall Lee Stevinson, Ruifeng Xu, Bartosz Chmielowski, J Wang, Frank Xiaoqing Liu, James M. Pellissier
Publikováno v:
Value in Health. 19:A154
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::39bd7d980cb7c80656e4062a2c4d9da4
https://doi.org/10.1016/j.jval.2016.03.1613
https://doi.org/10.1016/j.jval.2016.03.1613